JAK1 and COVID-19: In addition, Baricitinib and Ruxolitinib, targeted syntetic disease-modyfing anti-rheumatic drugs (tsDMARDs), have been tested as they selectively inhibit JAK1 and JAK2 kinase activity reducing the hyper-inflammation observed in COVID-19 (15, 16).